A Combined Therapy with Myo-Inositol and D-Chiro-Inositol Improves Endocrine Parameters and Insulin Resistance in PCOS Young Overweight Women
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Introduction.We evaluated the effects of a therapy that combines myo-inositol (MI) and D-chiro-inositol (DCI) in young overweight women affected by polycystic ovary syndrome (PCOS), characterized by oligo- or anovulation and hyperandrogenism, correlated to insulin resistance.Methods.We enrolled 46 patients affected by PCOS and, randomly, we assigned them to two groups, A and B, treated, respectively, with the association of MI plus DCI, in a 40 : 1 ratio, or with placebo (folic acid) for six months. Thus, we analyzed pretreatment and posttreatment FSH, LH, 17-beta-Estradiol, Sex Hormone Binding Globulin, androstenedione, free testosterone, dehydroepiandrosterone sulphate, HOMA index, and fasting glucose and insulin.Results.We recorded a statistically significant reduction of LH, free testosterone, fasting insulin, and HOMA index only in the group treated with the combined therapy of MI plus DCI; in the same patients, we observed a statistically significant increase of 17-beta-Estradiol levels.Conclusions.The combined therapy of MI plus DCI is effective in improving endocrine and metabolic parameters in young obese PCOS affected women.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“One study (n = 46) (29) with very low certainty evaluated MI 1.1 g + D chiro inositol 27.6 mg and FA 400μg taken daily compared to FA 400μg alone. No between-group comparisons were conducted. There was no difference between baseline and end of treatment for either arm for the outcomes of DHEAS, androstenedione, fasting glucose, and HOMA-IR. Improvements were reported in the intervention arm for”
From Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines (2024) · cites this paper as [29]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“administration of myo-inositol plus d-chiro-inositol in a ratio 40 : 1 reduced the metabolic and clinical alteration of PCOS”
From From Prediabetes to Type 2 Diabetes Mellitus in Women with Polycystic Ovary Syndrome: Lifestyle and Pharmacological Management (2020) · cites this paper as [91]
The cited source says what the claim attributes to it.
In the citing paper
“Three studies enrolled women with PCOS with an overweight or obese BMI classification (29, 44, 54).”
From Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines (2024) · cites this paper as [29]
The cited source says what the claim attributes to it.
In the citing paper
“Three compared the combination of 550 mg MI + 13.8 mg DCI + 200 mcg FA twice daily to FA alone (29, 37, 38).”
From Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines (2024) · cites this paper as [29]
The cited source says what the claim attributes to it.
In the citing paper
“Ten used FA at doses ranging from 200 to 400 mcg daily (25, 27, 29, 31, 34, 37, 46-49).”
From Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines (2024) · cites this paper as [29]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
- Retracted
Laganà, A. S., Barbaro, L., & Pizzo, A. (2014) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-014-3552-6 · Cited by 72
Retracted(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2004) · Human Reproduction · doi:10.1093/humrep/deh098 · Cited by 6,138
The Diagnosis of Polycystic Ovary Syndrome during Adolescence
Witchel, S. F., Oberfield, S., Rosenfield, R. L., Codner, E., Bonny, A., Ibáñez, L., Pena, A., Horikawa, R., Gomez-Lobo, V., Joel, D., et al. (2015) · Hormone Research in Paediatrics · doi:10.1159/000375530 · Cited by 3,113
Insulin Resistance and the Polycystic Ovary Syndrome: Mechanism and Implications for Pathogenesis*
Dunaif, A. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.6.0318 · Cited by 2,458
Epidemiology, diagnosis, and management of polycystic ovary syndrome
Sirmans, S., & Pate, K. (2013) · Clinical Epidemiology · doi:10.2147/clep.s37559 · Cited by 1,302
Insulin Resistance and the Polycystic Ovary Syndrome: Mechanism and Implications for Pathogenesis
Dunaif, A. (1997) · Endocrine Reviews · doi:10.1210/er.18.6.774 · Cited by 1,155
Correlation of Hyperandrogenism with Hyperinsulinism in Polycystic Ovarian Disease*
BURGHEN, G. A., GIVENS, J. R., & KITABCHI, A. E. (1980) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-50-1-113 · Cited by 919
Stepto, N. K., Cassar, S., Joham, A. E., Hutchison, S. K., Harrison, C. L., Goldstein, R. F., & Teede, H. J. (2013) · Human Reproduction · doi:10.1093/humrep/des463 · Cited by 747
Research works printed but not linked: 9
- 1988, Insulin resistance and hyperandrogenism: clinical syndromes and possible mechanisms, 293
- 2003, European Review for Medical and Pharmacological Sciences, 7, 151
- 2014, European Review for Medical and Pharmacological Sciences, 18, 1896
- 2002, Journal of the Pancreas, 3, 1
- 2009, European Review for Medical and Pharmacological Sciences, 13, 105
- 2007, European Review for Medical and Pharmacological Sciences, 11, 347
- 2012, European Review for Medical and Pharmacological Sciences, 16, 575
- 2013, European Review for Medical and Pharmacological Sciences, 17, 537
- 1993, Endocrinology, 132, 652, 10.1210/endo.132.2.8425485 · doi:10.1210/endo.132.2.8425485 · Paper page
Cited by
Metabolic Syndrome and PCOS: Pathogenesis and the Role of Metabolites
Chen, W., & Pang, Y. (2021) · Metabolites · doi:10.3390/metabo11120869 · Cited by 228
Inositol in Polycystic Ovary Syndrome: Restoring Fertility through a Pathophysiology-Based Approach
Laganà, A. S., Garzon, S., Casarin, J., Franchi, M., & Ghezzi, F. (2018) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2018.09.001 · Cited by 149
Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials
Unfer, V., Facchinetti, F., Orrù, B., Giordani, B., & Nestler, J. (2017) · Endocrine Connections · doi:10.1530/ec-17-0243 · Cited by 188
Antioxidants for female subfertility
Showell, M. G., Brown, J., Clarke, J., & Hart, R. J. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007807.pub2 · Cited by 184
Inositols: From Established Knowledge to Novel Approaches
Dinicola, S., Unfer, V., Facchinetti, F., Soulage, C. O., Greene, N. D., Bizzarri, M., Laganà, A. S., Chan, S.-Y., Bevilacqua, A., Pkhaladze, L., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910575 · Cited by 154
Effects of Inositol(s) in Women with PCOS: A Systematic Review of Randomized Controlled Trials
Unfer, V., Nestler, J. E., Kamenov, Z. A., Prapas, N., & Facchinetti, F. (2016) · International Journal of Endocrinology · doi:10.1155/2016/1849162 · Cited by 151
Greff, D., Juhász, A. E., Váncsa, S., Váradi, A., Sipos, Z., Szinte, J., Park, S., Hegyi, P., Nyirády, P., Ács, N., et al. (2023) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-023-01055-z · Cited by 143
“, one more RCT was included in the present analysis [31], and no difference was found in DHEAS levels after inositol treatment compared to placebo [19, 31].”
ResultAntioxidants for female subfertility
Showell, M. G., Mackenzie-Proctor, R., Jordan, V., & Hart, R. J. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007807.pub4 · Cited by 119
Inositols in polycystic ovary syndrome: An overview on the advances
Facchinetti, F., Unfer, V., Dewailly, D., Kamenov, Z. A., Diamanti-Kandarakis, E., Laganà, A. S., Nestler, J. E., & Soulage, C. O. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.02.002 · Cited by 102
Kamenov, Z., & Gateva, A. (2020) · Molecules · doi:10.3390/molecules25235566 · Cited by 100
“In a small patient cohort (n = 40) De Cicco et al. [129] demonstrated that the combination of MI +ALA for 6 months decreased BMI, waist-hip ratio, hirsutism score, AMH, ovarian volume, and antral follicle count, and an increase in the number of menstrual cycles.”
BackgroundInfluentialNatural Molecules in the Management of Polycystic Ovary Syndrome (PCOS): An Analytical Review
Iervolino, M., Lepore, E., Forte, G., Laganà, A. S., Buzzaccarini, G., & Unfer, V. (2021) · Nutrients · doi:10.3390/nu13051677 · Cited by 98
Cabrera-Cruz, H., Oróstica, L., Plaza-Parrochia, F., Torres-Pinto, I., Romero, C., & Vega, M. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00162.2019 · Cited by 98
Antioxidants for female subfertility
Showell, M. G., Mackenzie-Proctor, R., Jordan, V., & Hart, R. J. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007807.pub3 · Cited by 82
Inositol for subfertile women with polycystic ovary syndrome
Showell, M. G., Mackenzie-Proctor, R., Jordan, V., Hodgson, R., & Farquhar, C. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012378.pub2 · Cited by 75
Fitz, V., Graca, S., Mahalingaiah, S., Liu, J., Lai, L., Butt, A., Armour, M., Rao, V., Naidoo, D., Maunder, A., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad762 · Cited by 70
“Ten used FA at doses ranging from 200 to 400 mcg daily (25, 27, 29, 31, 34, 37, 46-49).”
BackgroundMethodInfluentialInositol Treatment for PCOS Should Be Science-Based and Not Arbitrary
Roseff, S., & Montenegro, M. (2020) · International Journal of Endocrinology · doi:10.1155/2020/6461254 · Cited by 49
Inositols and metabolic disorders: From farm to bedside
Caputo, M., Bona, E., Leone, I., Samà, M. T., Nuzzo, A., Ferrero, A., Aimaretti, G., Marzullo, P., & Prodam, F. (2020) · Journal of Traditional and Complementary Medicine · doi:10.1016/j.jtcme.2020.03.005 · Cited by 65
Facchinetti, F., Appetecchia, M., Aragona, C., Bevilacqua, A., Bezerra Espinola, M. S., Bizzarri, M., D’Anna, R., Dewailly, D., Diamanti-Kandarakis, E., Hernández Marín, I., et al. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1737675 · Cited by 63
Shokrpour, M., Foroozanfard, F., Afshar Ebrahimi, F., Vahedpoor, Z., Aghadavod, E., Ghaderi, A., & Asemi, Z. (2019) · Gynecological Endocrinology · doi:10.1080/09513590.2018.1540570 · Cited by 63
Effectiveness of myoinositol for polycystic ovary syndrome: a systematic review and meta-analysis
Zeng, L., & Yang, K. (2018) · Endocrine · doi:10.1007/s12020-017-1442-y · Cited by 59
“Only three [22, 25, 26] RCTs reported E2 level.”
BackgroundInfluentialInositols’ Importance in the Improvement of the Endocrine–Metabolic Profile in PCOS
Wojciechowska, A., Osowski, A., Jóźwik, M., Górecki, R., Rynkiewicz, A., & Wojtkiewicz, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225787 · Cited by 59
Altered Ovarian Inositol Ratios May Account for Pathological Steroidogenesis in PCOS
Unfer, V., Dinicola, S., Laganà, A. S., & Bizzarri, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197157 · Cited by 50
The Healing-Promoting Properties of Selected Cyclitols—A Review
Owczarczyk-Saczonek, A. B., Lahuta, L. B., Ligor, M., Placek, W. J., Górecki, R. J., & Buszewski, B. (2018) · Nutrients · doi:10.3390/nu10121891 · Cited by 57
Can pseudocereals modulate microbiota by functioning as probiotics or prebiotics?
Ugural, A., & Akyol, A. (2020) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2020.1846493 · Cited by 53
Gateva, A., Unfer, V., & Kamenov, Z. (2018) · Gynecological Endocrinology · doi:10.1080/09513590.2017.1421632 · Cited by 51
Inositols Depletion and Resistance: Principal Mechanisms and Therapeutic Strategies
Lepore, E., Lauretta, R., Bianchini, M., Mormando, M., Lorenzo, C. D., & Unfer, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136796 · Cited by 50
Advani, K., Batra, M., Tajpuriya, S., Gupta, R., Saraswat, A., Nagar, H. D., Makwana, L., Kshirsagar, S., Kaul, P., Ghosh, A. K., et al. (2019) · Journal of Obstetrics and Gynaecology · doi:10.1080/01443615.2019.1604644 · Cited by 48
Corrie, L., Gulati, M., Vishwas, S., Kapoor, B., Singh, S. K., Awasthi, A., & Khursheed, R. (2021) · Medical Hypotheses · doi:10.1016/j.mehy.2021.110644 · Cited by 43
Fraticelli, F., Celentano, C., Zecca, I. A., Di Vieste, G., Pintaudi, B., Liberati, M., Franzago, M., Di Nicola, M., & Vitacolonna, E. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1157-4 · Cited by 39
Pani, A., Gironi, I., Di Vieste, G., Mion, E., Bertuzzi, F., & Pintaudi, B. (2020) · International Journal of Endocrinology · doi:10.1155/2020/6276187 · Cited by 38
Tailoring treatment for PCOS phenotypes
Papadakis, G. E., Kandaraki, E., Garidou, A., Koutsaki, M., Papalou, O., Diamanti‐Kandarakis, E., & Peppa, Μ. (2020) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2021.1865152 · Cited by 38
Michell, R. H. (2018) · British Journal Of Nutrition · doi:10.1017/s0007114518000946 · Cited by 37
Garzon, S., Laganà, A. S., & Monastra, G. (2019) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1651839 · Cited by 37
Mendoza, N., Diaz-Ropero, M. P., Aragon, M., Maldonado, V., Llaneza, P., Lorente, J., Mendoza-Tesarik, R., Maldonado-Lobon, J., Olivares, M., & Fonolla, J. (2019) · Gynecological Endocrinology · doi:10.1080/09513590.2019.1576620 · Cited by 36
“This ratio has been effective in improving endocrine and metabolic parameters in obese PCOS women [9,10].”
BackgroundA PCOS Paradox: Does Inositol Therapy Find a Rationale in All the Different Phenotypes?
Unfer, V., Dinicola, S., & Russo, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076213 · Cited by 34
Jamilian, M., Farhat, P., Foroozanfard, F., Afshar Ebrahimi, F., Aghadavod, E., Bahmani, F., Badehnoosh, B., Jamilian, H., & Asemi, Z. (2017) · Clinical Endocrinology · doi:10.1111/cen.13366 · Cited by 31
Zhang, J., Xing, C., Zhao, H., & He, B. (2021) · Gynecological Endocrinology · doi:10.1080/09513590.2021.1926975 · Cited by 31
Inositols in the ovaries: activities and potential therapeutic applications
Laganà, A. S., Forte, G., Bizzarri, M., Kamenov, Z. A., Bianco, B. A. V., Kaya, C., Gitas, G., Alkatout, İ., Terzić, M., & Unfer, V. (2022) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2022.2071259 · Cited by 26
Graczyk, F., Orzechowska, B., Franz, D., Strzemski, M., Verpoorte, R., & Załuski, D. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.113636 · Cited by 24
Regulation of Inositol Biosynthesis: Balancing Health and Pathophysiology
Case, K. C., Salsaa, M., Yu, W., & Greenberg, M. L. (2018) · Handbook of experimental pharmacology · doi:10.1007/164_2018_181 · Cited by 23
Bahadur, A., Arora, H., Ravi, A. K., Naithani, M., Bahurupi, Y., Chaturvedi, J., Ajmani, M., & Mundhra, R. (2021) · Cureus · doi:10.7759/cureus.15510 · Cited by 22
“[12] conducted a study on 46 patients affected by PCOS.”
BackgroundCurrent treatment for polycystic ovary syndrome: focus on adolescence
Street, M. E., Cirillo, F., Catellani, C., Dauriz, M., Lazzeroni, P., Sartori, C., & Moghetti, P. (2020) · Minerva Pediatrics · doi:10.23736/s0026-4946.20.05861-2 · Cited by 21
Myo-Inositol and Its Derivatives: Their Roles in the Challenges of Infertility
Placidi, M., Casoli, G., Tatone, C., Emidio, G. D., & Bevilacqua, A. (2024) · Biology · doi:10.3390/biology13110936 · Cited by 20
Nutraceuticals and polycystic ovary syndrome: a systematic review of the literature
Menichini, D., Ughetti, C., Monari, F., Vinci, P. L. D., Neri, I., & Facchinetti, F. (2022) · Gynecological Endocrinology · doi:10.1080/09513590.2022.2089106 · Cited by 20
Duliński, R., Zdaniewicz, M., Pater, A., & Żyła, K. (2019) · Journal of the American Society of Brewing Chemists · doi:10.1080/03610470.2019.1589910 · Cited by 20
Determination of carbohydrates in the herbal antidiabetic mixtures by GC-MC
Savych, A., Marchyshyn, S. М., & Мілян, І. І. (2020) · Acta Pharmaceutica · doi:10.2478/acph-2021-0026 · Cited by 17
Polycystic ovary syndrome in Latin American populations: What is known and what remains unresolved
Abruzzese, G. A., Velázquez, M. E., Cerrone, G. E., & Motta, A. B. (2022) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2022.106195 · Cited by 16
Management of polycystic ovary syndrome among Indian women using myo‐inositol and D-chiro-inositol
Vyas, L., Raiturker, A. P., Sud, S., Goyyal, P., Abhyankar, M., Revankar, S., & Walia, S. (2022) · Bioinformation · doi:10.6026/97320630018103 · Cited by 15
Džafić, A., & Žuljević, S. O. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.102570 · Cited by 15
Basciani, S., Nordio, M., Dinicola, S., Unfer, V., & Gnessi, L. (2023) · Nutrients · doi:10.3390/nu15143142 · Cited by 14
Polycystic ovary syndrome: new and promising treatment methods
Муратовна, Г. Д., Sheremetyeva, E. V., Kalashnikova, M. F., Dzgoeva, F. K., & Алборова, Е. Т. (2024) · Problems of Endocrinology · doi:10.14341/probl13400 · Cited by 13
Евгеньевна, Ч. Г., Udovichenko, M. A., & Naydukova, A. A. (2019) · Doctor Ru · doi:10.31550/1727-2378-2019-166-11-55-60 · Cited by 11
Nani, A., Bertuzzi, F., Meneghini, E., Mion, E., & Pintaudi, B. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12247650 · Cited by 10
Rani, C., Deeba, F., Ishrat, S., Banu, J., Jahan, S., Nazneen, S., Akter, S., & Chowdhury, P. R. (2022) · International Journal of Reproduction Contraception Obstetrics and Gynecology · doi:10.18203/2320-1770.ijrcog20222785 · Cited by 10
The role of myo-inositol supplement in assisted reproductive techniques
Bashiri, Z., Sheibak, N., Amjadi, F., & Zandieh, Z. (2022) · Human Fertility · doi:10.1080/14647273.2022.2073273 · Cited by 8
Çelik, Z. M., Kurnaz, D., Özcan, A., Keskin, E., Unlugedik, E., & Aktaç, Ş. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70307 · Cited by 7
Corrie, L., Singh, S. K., Gulati, M., Awasthi, A., Khursheed, R., Kaur, J., & Vishwas, S. (2022) · Current Women s Health Reviews · doi:10.2174/1573404818666220329123334 · Cited by 6
An evaluation of the available pharmacotherapy for the treatment of hirsutism
Asfour, L., Kazmi, A., & Sinclair, R. D. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2198088 · Cited by 6
Aziz, M. (2023) · Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal · doi:10.26685/urncst.473 · Cited by 6
Metformin and Myo-Inositol: A Comparative Analysis
Russo, M., Oliva, M. M., Nordio, M., Porcaro, G., & Unfer, V. (2025) · Gynecologic and Obstetric Investigation · doi:10.1159/000549646 · Cited by 5
Use of Inositols in Polycystic Ovary Syndrome
Pustotina, O. A. (2020) · Effective Pharmacotherapy · doi:10.33978/2307-3586-2020-16-28-24-34 · Cited by 5
Street, M. E., Casadei, F., Bari, E. R. D., Ferraboschi, F., Montani, A. G., Mele, M. L., Shulhai, A.-M., & Esposito, S. (2025) · Nutrients · doi:10.3390/nu17091487 · Cited by 5
Sánchez, A. A., Castillo, N., García-Vidal, E., Chadid, M. L., Ballada, C. S., Ricart, G. V., & Pellens, V. T. (2024) · Clinical Medicine Insights Case Reports · doi:10.1177/11795476241242265 · Cited by 4
Юрьевна, П. В., Alyautdina, O. S., & Sosna, N. A. (2021) · Russian Journal of Human Reproduction · doi:10.17116/repro20212704197 · Cited by 4
Alyautdina, O. S., Юрьевна, П. В., & Krylova, E. (2021) · V F Snegirev Archives of Obstetrics and Gynecology · doi:10.17816/2313-8726-2021-8-2-81-92 · Cited by 3
Use of myo-inositol in the treatment of PCOS symptoms in adolescents
Pkhaladze, L., Unfer, V., & Dewailly, D. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91673-8.00001-7 · Cited by 3
Delavar, M. A., Mirabi, P., Rosenkranz, S. K., Alibabaei-Omran, F., Ahmadi, N., & Ghorbani, Z. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01980-6 · Cited by 3
ПЕРСПЕКТИВИ ВИКОРИСТАННЯ ІНОЗИТОЛУ У ЖІНОК З СИНДРОМОМ ПОЛІКІСТОЗНИХ ЯЄЧНИКІВ (ОГЛЯД ЛІТЕРАТУРИ)
Khmil, M. S., Досвальд, А. С. Х., Khmil, S. V., & Підгайна, І. Я. (2019) · Вісник соціальної гігієни та організації охорони здоров я України · doi:10.11603/1681-2786.2018.4.10035 · Cited by 3
Inositols and other supplements in the management of PCOS
Unfer, V., Monastra, G., Tilotta, M., Forte, G., & Dinicola, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823045-9.00014-6 · Cited by 3
Khan, R. B., Sarosh, M., & Anwer, S. (2022) · Pakistan Journal of Medical and Health Sciences · doi:10.53350/pjmhs2216121 · Cited by 2
Tienforti, D., Puocci, G., Venditti, C., Gizzi, V., Pisano, C., Cocci, E., Perfetto, E., D'Alessandro, F., Spagnolo, L., Baroni, M. G., et al. (2026) · Clinical Endocrinology · doi:10.1111/cen.70140 · Cited by 2
Therapeutic options for pre-gravidary training in women with a history of combined infertility
Туманова, Л. Е., & Kolomiets, E. V. (2022) · Reproductive health of woman · doi:10.30841/2708-8731.2.2022.261808 · Cited by 2
D-Chiro Inositol in Lowering Androgen Levels in Pcos Patients
Ashraf, A., Kundi, M. B., Arif, S. U., Asif, M., Ilyas, M., & Rehan, H. (2022) · Pakistan Journal of Medical and Health Sciences · doi:10.53350/pjmhs221611010 · Cited by 2
TRATAMENTO DA INFERTILIDADE EM PACIENTES COM SÍNDROME DOS OVÁRIOS POLICÍSTICOS
Sampaio, B. R., Dezen, M. C., Lourini, A. L. A., Vidal, V. M. D. S., Silveira, E. R., Fontanella, R. S. P., Rosa, C. L., Salvador, D. L. V. F., de Paulo, L. G., Pereira, J. R., et al. (2024) · Brazilian Journal of Implantology and Health Sciences · doi:10.36557/2674-8169.2024v6n7p1115-1136 · Cited by 2
Soluble peptidoglycan production from the waste peels of pineapple Ananas comosus (L.) Merr.
Ker, Y.-B., Peng, C.-C., Chen, Y.-S., Chen, K., kuanchou@tmu.edu.tw, R. S. H. N. A. Y. N. T., Shen, K., kuanchou@tmu.edu.tw, R. S. H. N. A. Y. N. T., Peng, R. Y., & kuanchou@tmu.edu.tw, R. S. H. N. A. Y. N. T. (2019) · Fruits · doi:10.17660/th2019/74.1.5 · Cited by 2
Cantelmi, T., & Lorenzo, C. D. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91673-8.00003-0 · Cited by 2
Uso terapêutico de mio-inositol como tratamento em pacientes com síndrome do ovário policístico
Jonas, C. F. (2019) · Lume (Universidade Federal do Rio Grande do Sul) · Cited by 2
Malvi, A., Chaturvedi, A., Mehta, S. V., Sonkusare, K., & Dave, N. (2019) · The New Indian Journal of OBGYN · doi:10.21276/obgyn.2019.5.2.2 · Cited by 1
Inositol and herbal substances as elements of complementary therapy in patients with PCOS
Aab, A., Zarańska, J., Kędra, K., MICHALIK, I., Bielak, M., & Zarański, B. (2023) · Journal of Education Health and Sport · doi:10.12775/jehs.2023.16.01.012 · Cited by 1
Inositols in Polycystic Ovary Syndrome: A Comprehensive Review
Badawy, A., Mohamedh, ., & Fahmy, S. S. E. (2025) · Aswan Africa Obstetrics and Gynecology Journal · doi:10.21608/aaogj.2025.419927.1021 · Cited by 1
Taş, M., & Özçelik, B. (2019) · Journal of Surgery and Medicine · doi:10.28982/josam.624097 · Cited by 1
Role of inositol and its isomers in glucose metabolism
Ночвіна, О. А., & Slyvka, E. (2021) · Reproductive Endocrinology · doi:10.18370/2309-4117.2021.62.104-109 · Cited by 1
Association of insulin resistance and PCOS and its effect on women’s reproductive function
Burlakova, E. S., Merkulova, A. E., Логинова, Е. А., Константиновна, К. С., & Od, K. (2022) · Russian Journal of Human Reproduction · doi:10.17116/repro20222802147 · Cited by 1
ВПЛИВ ІНОЗИТОЛУ НА ОРГАНІЗМ ТА РЕПРОДУКТИВНУ ФУНКЦІЮ ЖІНКИ
Khmil, S. V., Денефіль, О. В., Терлецька, Н. Ю., Khmil, M. S., & Petryshyn, N. Y. (2023) · Здобутки клінічної і експериментальної медицини · doi:10.11603/1811-2471.2022.v.i4.13495 · Cited by 1
Polycystic Ovary Syndrome (PCOS) Inhibitory Drug Screening from Selective Inositols
(2023) · Toxicology and Applied Pharmacology Insights · doi:10.33140/tapi.06.01.18 · Cited by 1
Effect of Myo-Inositol in Treating Polycystic Ovary Syndrome (PCOS): A Review
Alam, S. (2024) · Journal of Obstetrics and Gynecological Surgery · doi:10.52916/jogs244039 · Cited by 1
D-Chiro-inositol in PCOS: the myths and what we know about the reality
Unfer, V. (2022) · International Journal of Food Sciences and Nutrition · doi:10.1080/09637486.2022.2089638 · Cited by 1
A unique variant of spontaneous ovarian hyperstimulation syndrome: case report
Rohatgi, T. B., & Buckshee, K. (2017) · International Journal of Reproduction Contraception Obstetrics and Gynecology · doi:10.18203/2320-1770.ijrcog20174087
Polycystic Ovary Syndrome: An Overview of a Complex, Heterogenous Genetic Condition
Nair, S., Nkamga, Y., & Hoover‐Hankerson, B. (2020) · Springer eBooks · doi:10.1007/978-3-030-33946-3_9
The Effect Myo-Inositol and D-Chiro-Inositol Co-Supplementation in Women with PCOS: A review
Meliana, A., Wilujeng, S. G., & Qorib, M. F. (2022) · International Journal of Research Publications · doi:10.47119/ijrp10011311120214154
Overcoming inositol resistance
Kamenov, Z. A., & Oliva, M. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91673-8.00009-1
Pandya, M. R., Pandya, N. M., Narayanan, V., Adroja, K. S., & Patel, V. C. (2023) · Indian Journal of Obstetrics and Gynecology Research · doi:10.18231/j.ijogr.2023.092
Saadia, Z., Memon, M., & Memon, M. (2025) · World Academy of Sciences Journal · doi:10.3892/wasj.2025.360
Nessa, A., Akter, S., Hossain, F., Alam, H., Sultana, R., Islam, M. A., Tarique, M. M. A., & Banu, J. (2025) · International Journal of Reproduction Contraception Obstetrics and Gynecology · doi:10.18203/2320-1770.ijrcog20251971
Ghosh, A., Saha, L. R., Hossain, F., Alam, H., Tarique, M. M. A., Sultana, R., Sharma, A. K., & Banu, J. (2025) · International Journal of Reproduction Contraception Obstetrics and Gynecology · doi:10.18203/2320-1770.ijrcog20252340
Nutritional supplementation and its role in Indian women\'s health: An expert perspective study
Manjula, S., & Krishna Kumar, M. (2025) · IP Journal of Nutrition Metabolism and Health Science · doi:10.18231/j.ijnmhs.2025.013
“Effect of Myoinositol in Lipid Profile and Insulin Resistance in PCOS Patients.”
Sony, A. (2025) · American Journal of Psychiatric Rehabilitation · doi:10.69980/ajpr.v28i5.640
Dasgupta, S., Kumar, P., Biswas, P. K., Kamat, J., Ahire, P., Fatima, K., Hadwale, A., Nadkarni, S., Narvekar, P., Gaitonde, V., et al. (2025) · International Journal of Reproduction Contraception Obstetrics and Gynecology · doi:10.18203/2320-1770.ijrcog20253506
Greff, D., Juhász, A. E., Váncsa, S., Váradi, A., Sipos, Z., Szinte, J., Park, S., Hegyi, P., Nyírády, P., Ács, N., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22601932
Mejías Jordan, P. (2025) · RIULL (Universidad de La Laguna)
Metadata
- Authors
- Benelli, E., Del Ghianda, S., Di Cosmo, C., & Tonacchera, M.
- Affiliations
- University of Pisa (IT)
- Department of Clinical and Experimental Medicine, Section of Endocrinology, University Hospital of Pisa, Via Paradisa 2, 56124 Pisa, Italy
- Corresponding author
- Tonacchera, Massimo
- Venue
- International Journal of Endocrinology
- Publisher
- Wiley
- Published
- 2016
- Volume
- 2016
- Pages
- 1-5
- ISSN
- 1687-8337 (ISSN-L)
- 1687-8345
- PMC
- PMC4963579
- OpenAlex
- W2469453300
- Cited by
- 100
- References
- 44
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 4 · 2023: 16 · 2022: 15 · 2021: 12 · 2020: 15 · 2019: 12 · 2018: 7 · 2017: 4 · 2016: 1
- FWCI
- 10.63
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- International Journal of Endocrinology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Reproductive Medicine › Reproductive Biology and Fertility
- Keywords
- polycystic ovary syndrome, myo-inositol, D-chiro-inositol, insulin resistance, hyperandrogenism, overweight women, luteinizing hormone, free testosterone, estradiol, sex hormone-binding globulin, HOMA index, anovulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.